S447
Clinical - Gynaecological
ESTRO 2026
demonstrated significantly greater BMD preservation versus controls (p = 0.0045, Figure 2). Including MHP status did not alter the association in either model (Figure 2).
between vertebral radiation dose and BMD decline, with a threshold near 5 Gy. MHP participants showed greater bone preservation than controls. Future multicentre studies should validate dose effects and integrate bone-sparing strategies into treatment planning. Keywords: bone mineral density, radiotherapy toxicity, trial Hypofractionated Chemoradiotherapy for Locally Advanced Cervical Cancer: Results from the Phase II Randomized HEROICC Trial Lucas C. Mendez 1 , Eric Leung 2 , Hamid Raziee 3 , Melanie Davidson 4 , Donna Murrell 5 , Douglas A Hoover 5 , Bryan Schaly 5 , Andrew Warner 1 , Vikram Velker 1 , David D'Souza 1 1 Radiation Oncology, London Health Sciences Proffered Paper 2296 Centre, London, Canada. 2 Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada. 3 Radiation Oncology, BC Cancer, Kelowna, Canada. 4 Medical Physics, BC Cancer, Kelowna, Canada. 5 Medical Physics, London Health Sciences Centre, London, Canada Purpose/Objective: Cervical cancer remains a major health burden in developing countries, where radiotherapy (RT) resources are often limited and access is not universal. Hypofractionated radiotherapy (HypoRT) may help address this gap by delivering a comparable biological tumour dose in fewer treatment sessions. Material/Methods: The HEROICC trial (NCT04583254) is a multi- institutional, randomized, phase II, feasibility study designed to assess the enrollment and treatment feasibility of HypoRT for cervical cancer within the Canadian setting. Eligible patients had histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix; were candidates for concurrent
Conclusion: A significant dose-response was observed
Made with FlippingBook - Share PDF online